Pyrrho Capital Management’s Travere Therapeutics TVTX Stock Holding History

Pyrrho Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-67,820	Closed	-$926K	–	35
2016 Q1	$926K	Buy	+67,820	New	+$1.03M	1.3%	14
2015 Q4	–	Sell	-37,040	Closed	-$750K	–	32
2015 Q3	$750K	Buy	+37,040	New	+$1.1M	0.65%	36

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Pyrrho Capital Management's TVTX Position: Q2 2016 in Review

Pyrrho Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2016, closing a stake of 67,820 shares — an estimated $926K sold.

Pyrrho Capital Management first reported a position in TVTX in Q3 2015 and held it in 2 quarters. The position peaked at $926K in Q1 2016. 111 funds tracked by Wall St. Rank hold TVTX as of Q2 2016.

Pyrrho Capital Management reported no remaining Travere Therapeutics position as of Q2 2016 after selling out during the quarter.
Pyrrho Capital Management sold 67,820 Travere Therapeutics shares in Q2 2016, an estimated $926K.
Pyrrho Capital Management first reported a position in Travere Therapeutics in Q3 2015 and held it in 2 quarters.
Pyrrho Capital Management's Travere Therapeutics position peaked at $926K in Q1 2016.
111 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2016.

Based on Pyrrho Capital Management's 13F filing for Q2 2016, filed 27 Jul 2016.